ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 099,69
0,09%
Dow Jones
39 671,04
-0,51%
DAX
18 689,51
0,04%
Brent Oil
81,825
0,36%
Bitcoin
69 606,15
0,73%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. uniQure NV (QURE)

  7. uniQure NV (QURE) Actualités

QURE

uniQure NV (QURE)

uniQure NV
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:QURE
DateHeureSourceTitreSymboleSociété
07/05/202414h03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QUREuniQure NV
07/05/202413h57Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:QUREuniQure NV
07/05/202413h05GlobeNewswire Inc.uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company ProgressNASDAQ:QUREuniQure NV
05/03/202423h14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:QUREuniQure NV
28/02/202414h29Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:QUREuniQure NV
28/02/202413h05GlobeNewswire Inc.uniQure Announces 2023 Financial Results and Highlights Recent Company ProgressNASDAQ:QUREuniQure NV
26/02/202422h46Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:QUREuniQure NV
13/02/202422h33Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:QUREuniQure NV
19/12/202313h05GlobeNewswire Inc.uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s DiseaseNASDAQ:QUREuniQure NV
12/12/202301h30PR Newswire (US)CSL Behring's HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia BNASDAQ:QUREuniQure NV
08/12/202313h05GlobeNewswire Inc.uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:QUREuniQure NV
29/11/202313h05GlobeNewswire Inc.uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry DiseaseNASDAQ:QUREuniQure NV
07/11/202313h05GlobeNewswire Inc.uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company ProgressNASDAQ:QUREuniQure NV
27/10/202316h00PR Newswire (US)CSL and uniQure Win 2023 Prix Galien USA AwardNASDAQ:QUREuniQure NV
26/10/202320h38PR Newswire (Canada)Santé Canada autorise HEMGENIX® de CSL (étranacogène dézaparvovec) comme première thérapie génique pour l'hémophilie BNASDAQ:QUREuniQure NV
26/10/202320h14PR Newswire (Canada)Health Canada Authorizes CSL's HEMGENIX® (etranacogene dezaparvovec) as First Gene Therapy for Hemophilia BNASDAQ:QUREuniQure NV
24/10/202313h05GlobeNewswire Inc.uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual MeetingNASDAQ:QUREuniQure NV
06/10/202312h33Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:QUREuniQure NV
06/10/202312h32Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:QUREuniQure NV
05/10/202313h05GlobeNewswire Inc.uniQure Announces Strategic Reorganization to Reduce Operating Expenses and Support Advancement of Multiple Clinical-Stage ProgramsNASDAQ:QUREuniQure NV
03/10/202303h50Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:QUREuniQure NV
05/09/202319h59Dow Jones NewsRe/Max, UniQure and Trinseo Fall to 52-Week Lows on Exit From S&P SmallCap 600NASDAQ:QUREuniQure NV
05/09/202313h05GlobeNewswire Inc.uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe EpilepsyNASDAQ:QUREuniQure NV
02/09/202300h51PR Newswire (US)Blackstone and Airbnb Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600NASDAQ:QUREuniQure NV
01/08/202313h05GlobeNewswire Inc.uniQure Announces Second Quarter 2023 Financial Results and Highlights Recent Company ProgressNASDAQ:QUREuniQure NV
26/06/202313h11GlobeNewswire Inc.uniQure Announces Leadership Addition to Support Advancement of Clinical ProgramsNASDAQ:QUREuniQure NV
22/06/202323h00Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:QUREuniQure NV
21/06/202313h05GlobeNewswire Inc.uniQure Announces Update on U.S. Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s DiseaseNASDAQ:QUREuniQure NV
20/06/202323h31Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:QUREuniQure NV
20/06/202313h05GlobeNewswire Inc.uniQure announces achievement of $100 million milestone related to hemophilia B gene therapyNASDAQ:QUREuniQure NV
 Showing the most relevant articles for your search:NASDAQ:QURE

Dernières Valeurs Consultées

LSE
AMG
BIT
P1ZH46
NLBNPIT1ZH46 20241220 12
BIT
P1ZNP9
NLBNPIT1ZNP9 20241220 15
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés